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Abstract: The goal of epilepsy therapy is to help patients achieve seizure freedom without adverse effects. While mono-
therapy is preferable in epilepsy treatment, many patients fail a first drug due to lack of efficacy or failure to tolerate an 
initial medication, necessitating an alteration in therapy. Sudden changes between monotherapies are rarely feasible and 
sometimes deleterious given potential hazards of acute seizure exacerbation or intolerable adverse effects. The preferred 
method for converting between monotherapies is transitional polytherapy, a process involving initiation of a new antiepi-
leptic drug (AED) and adjusting it toward a target dose while maintaining or reducing the dose of the baseline medication. 
A fixed-dose titration strategy of maintaining the baseline drug dose while titrating the new medication is preferable when 
breakthrough seizures are occurring and no adverse effects are present. However, a flexible titration strategy involving re-
duction of the baseline drug dose to ensure adequate tolerability of the new adjunctive medication is preferred when pa-
tients are already experiencing adverse effects. This article reviews pharmacokinetic considerations pertinent for ensuring 
successful transitional polytherapy with the standard and newer antiepileptic drugs. Practical consensus recommendations 
“from an expect panel (SPECTRA, Study by a Panel of Experts Considerations for Therapy Replacement and Antiepilep-
tics) for a successful monotherapy” AED conversions are then summarized. Transitional polytherapy is most successful 
when clinicians appropriately manage the titration strategy and consider pharmacokinetic factors germane to the baseline 
and new adjunctive medication. 
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INTRODUCTION 
  Epilepsy is characterized by two or more unprovoked 
seizures that may be either partial (focal or localized) or gen-
eralized. A single seizure does not define epilepsy because 
the probability of having a second seizure ranges between 
20% and 70%. Therefore, depending on the underlying risk 
factors, therapy with antiepileptic drugs (AEDs) is usually 
not initiated until a patient has a second seizure. However, 
when it is established that a patient has epilepsy (i.e., two or 
more unprovoked seizures), rapid initiation of therapy to 
control seizures is appropriate. 
  The goal of seizure therapy is producing seizure freedom 
without adverse effects of treatment. The choice of the initial 
AED involves selecting a drug that is appropriate for the 
patient’s seizure type, the safety profile for that individual 
and the patient’s ability to tolerate the drug, the potential for 
interactions with other drugs, the pharmacokinetics and 
pharmacodynamics that determine the dosing schedule, a 
formulation that the patient can ingest, and the expense.
  While monotherapy is preferable in epilepsy treatment, 
many patients fail a first drug due to lack of efficacy or fail-
ure to tolerate an initial medication, necessitating an altera-
tion in therapy. Sudden changes between monotherapies are 
rarely feasible and sometimes deleterious since they expose 
the patient to potential hazards of acute seizure exacerbation 
or intolerable adverse effects. The preferred method for con- 
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verting between monotherapies is transitional polytherapy, a 
process involving initiation of a new antiepileptic drug 
(AED) and adjusting it toward a target dose while maintain-
ing the baseline medication. A flexible titration strategy in-
volving reduction of a baseline drug dose to ensure adequate 
tolerability of the new adjunctive medication is preferred. 
This article reviews pharmacokinetic considerations perti-
nent for ensuring successful transitional polytherapy with the 
standard and newer antiepileptic drugs. Practical consensus 
recommendations from an expert panel for successful mono-
therapy to monotherapy AED conversions are then summa-
rized. Transitional polytherapy is most successful when cli-
nicians appropriately manage the titration strategy and con-
sider pharmacokinetic factors germane to the baseline and 
new adjunctive medication.
MONOTHERAPY 
  A guiding principal of AED therapy is the initiation of 
therapy with a single AED (ie, monotherapy). While AED 
therapy formerly was often initiated with combination ther-
apy (eg, phenytoin and phenobarbital), the principle of 
monotherapy was established in the 1980s, based on studies 
that demonstrated comparable efficacy and superior toler-
ability of monotherapy compared to polytherapy. Initial ther-
apy of newly diagnosed epilepsy with combination AEDs is 
inappropriate because most patients respond to a single AED 
[27,28]. The use of a second AED increases a patient’s drug 
load, adding to the number and severity of side effects. A 
second drug also increases the potential for drug-drug inter-
actions and makes drug regimens more complex. More com-
plex drug regimens result in a lower rate of compliance (ad-
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therapy are that if two AEDs are used initially, it is difficult 
to titrate each drug individually, and the use of combination 
therapy is more expensive. Therefore, while combination 
therapy may be appropriate in many refractory patients in 
chronic epilepsy treatment, it is not appropriate as initial 
therapy. Many clinicians feel that polytherapy is not appro-
priate until a patient has failed two or three trials of mono-
therapy with appropriately selected AEDs for that patient’s 
epilepsy syndrome. 
  A factor that limits the use of monotherapy with some 
newer AEDs is the stringent FDA approval process for 
monotherapy treatment in epilepsy, which requires demon-
stration of superiority to another treatment, usually arising 
from a large randomized controlled trial utilizing an active 
control design. AEDs may be approved for use in some 
countries following equivalency trials. In these trials, the 
new AED will be compared to an established AED such as 
carbamazepine. If a new drug is found to be at least as effec-
tive as the standard, the drug is approved following proof of 
equivalency or non-inferiority. The FDA viewpoint is that 
while drugs may be equivalent, they may be equally ineffec-
tive. In some studies, a low and presumably ineffective dose 
of a standard AED, such as valproic acid, was used in place 
of the placebo. While a placebo-controlled study is consid-
ered the “gold standard” for proof of principle for efficacy in 
clinical trials, most experts would consider treatment of 
newly diagnosed epilepsy with a placebo to be unethical. 
Therefore, all of the newer or “second-generation” AEDs 
beginning with the approval of felbamate in 1993 have been 
initially studied as add-on therapy for patients with uncon-
trolled partial seizures with or without secondary generaliza-
tion. Entry criteria for such studies typically require continu-
ing seizures despite therapy with one to three AEDs in ade-
quate doses. Therefore, initial efficacy is determined as 
combination therapy. 
  Drugs that are efficacious as combination therapy may 
not be efficacious as monotherapy. A drug which is proven 
to be efficacious for seizure reduction when given as adjun-
ctive therapy may only be effective due to a pharmacody-
namic combined effect with the original baseline drug; that 
is, the second AED may require the additional seizure sup-
pressive activity of the first drug to be effective. There are 
several potential clinical trial designs for evaluating the effi-
cacy of an AED for use as monotherapy depending on its 
pharmacokinetics and pharmacodynamics. One of the most 
frequently used designs is a so-called conversion to mono-
therapy design, in which the patient is initially treated with 
combination therapy, and then the initial AED is discontin-
ued to assess the efficacy of the new drug alone. A few of 
the second-generation AEDs have conducted trials to dem-
onstrate efficacy as monotherapy. For example, lamotrigine, 
topiramate, oxcarbazepine, and felbamate have been demon-
strated to be effective as monotherapy and have received 
FDA approval for use as monotherapy, while gabapentin also 
has evidence for monotherapy use [18]. A recent study has 
also documented the efficacy of levetiracetam monotherapy 
efficacy in large comparator trial designs [7]. 
  The initial choice of an AED has little effect on the re-
sponse rate as long as the AED is appropriate for the seizure 
type [28]. In an assessment of a large number of drug naïve 
patients with newly diagnosed epilepsy, almost 50% of pa-
tients will respond to an AED regardless of which drug is 
utilized [28]. Thus, factors such as tolerability, safety, dosing 
regimen, and expense are more important in selecting an 
AED. However, if 50% of patients respond to initial therapy, 
this implies that another 50% do not respond to an initial 
AED. Many clinicians feel that patients should fail two or 
three trials of monotherapy before chronic polytherapy is 
entertained. 
  A sudden overnight switch from one AED to another is 
ill advised, given the efficacy of the newly planned AED has 
not yet been established, placing the patient at risk for cata-
strophic seizure worsening, raising the risk for acute repeti-
tive seizures or even status epilepticus. Conversely, patients 
may not tolerate a rapid titration to target dose of the newly 
planned AED even if it is effective from its inception. Most 
clinicians agree that a gradual conversion process to a new 
planned AED monotherapy is the safest and most tolerable 
approach, a process that may be called transitional polyther-
apy. Transitional polytherapy involves a gradual titration of 
the newly planned AED toward a target dose, and, after this 
is achieved, a gradual withdrawal of the baseline drug. Dur-
ing this process, if intolerable adverse effects emerge, accel-
erating the withdrawal of the baseline initial drug may be 
considered. 
  Patients who fail to respond to their initial AED will need 
transitional polytherapy during conversion to a new mono-
therapy with another AED. Another reason requiring transi-
tion to a new medication is that a patient may be unable to 
tolerate their initial medication, irrespective of clinical effec-
tiveness of that therapy. Such patients also need transitional 
polytherapy during a switch to another new AED monother-
apy. Therefore, patients who fail to achieve seizure control, 
and/or are unable tolerate an initial AED, have need for tran-
sitional polytherapy. 
TRANSITIONALPOLYTHERAPYDURINGCONVER-
SION FROM MONOTHERAPY TO MONOTHERAPY 
  There are many reasons why a given patient may not 
tolerate a specific AED. Some patients have idiosyncratic 
reactions necessitating removal of a drug. For example, 
phenytoin, carbamazepine, and lamotrigine are associated 
with allergic rash. In some cases, this rash may progress to a 
life-threatening condition such as the Stevens-Johnson syn-
drome or toxic epidermal necrolysis (TEN). More com-
monly, adverse effects may not be acute or life threatening 
but are troublesome to the patient. For example, some pa-
tients note diplopia, blurred vision, drowsiness, and lethargy 
with carbamazepine. While these CNS adverse effects may 
be reduced with a controlled release formulation of carba-
mazepine or a lower dose, the effects may still limit a pa-
tient’s quality of life (QoL). There is a negative linear rela-
tionship between adverse effects and patient QoL: as adverse 
events increase, patient QoL decreases [20]. In women of 
childbearing potential, teratogenic effects of specific AEDs 
are of concern. Several pregnancy registries have raised con-
cerns regarding the use of valproic acid in women of child 
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adhering to a specific drug regimen, especially regimens 
involving multiple daily doses; if the AED has to be given 
three or four times per day, adherence greatly diminishes [9]. 
Also, some patients, especially children and the elderly, may 
find that they cannot ingest certain AED formulations. These 
patients may need to be switched to a drug that is available 
as a sprinkle, liquid, or smaller pill size. Finally, changes in 
financial status or insurance coverage may make acquisition 
of several AEDs difficult. 
  The conversion of a patient on monotherapy with an ini-
tial baseline AED to a new planned AED may be rapid or 
slow. A rapid conversion would involve abruptly stopping 
the initial baseline drug and starting the newly planned drug. 
This is usually only done in a situation where the person has 
experienced a life-threatening reaction to an AED. The sud-
den withdrawal of an AED may precipitate a withdrawal 
seizure. Generally, a patient will be more slowly converted 
from an initial baseline AED to a new planned AED so that 
there is a transitional period of polytherapy. One method for 
a slow conversion is to begin to slowly reduce the dose of an 
initial baseline AED and to initiate a titration process with a 
new planned AED. Another method, generally preferred   
especially in patients who are tolerating an initial baseline 
drug but who have not achieved seizure control, maintains 
the dose of the baseline drug while the dose of the planned 
drug is titrated to the desired amount. Then the baseline drug 
is tapered off.  
  The relative merits of further titration of the current drug 
toward the goal of high dose monotherapy, or alternatively 
initiating transitional polytherapy, is a central aspect of epi-
lepsy care. Unfortunately, there is no evidence to guide this 
decision point, making the process more art than science 
(please see suggested algorithmic approach toward pursuit of 
high dose monotherapy vs. initiation of polytherapy shown 
in (Fig. 1)). In newly diagnosed epilepsy, approximately 
50% of patients respond to the first AED utilized, and the 
majorityof patients respond to moderate target doses [26,27]. 
Exceptional patients clearly benefit from further vigorous 
titration of initial AED monotherapy. For patients that dem-
onstrate incremental improvements in seizure frequency as 
AED dosing is increased without reaching a plateau in thera-
peutic effect, additional titration of high dose AED mono-
therapy is entirely reasonable and preferable as the logical 
goal of epilepsy care is to produce seizure freedom. Occa- 
Fig. (1). Suggested Algorithmic Approach for Initiating and Carrying Out Transitional Polytherapy. There are two potential pathways 
for using the algorithm which consider the alternative common clinical scenarios of either breakthrough seizures (beginning in upper left 
corner) or adverse effects (lower right corner) during initial monotherapy. If a patient experiences breakthrough seizures without adverse 
effects on monotherapy, the algorithm suggests further titration of high dose monotherapy until a “therapeutic plateau” (i.e., a maximal level 
of seizure reduction response) is reached, then progressing to a “Fixed-dose” transitional polytherapy strategy. Alternatively, if the patient 
experiences adverse effects, a “Flex-dose” strategy is most appropriate, which involves simultaneous reduction and tapering of the primary 
baseline antiepileptic drug (AED) while titrating the new adjunctive AED. The anticipated successful outcomes of these strategies would be 
seizure freedom on high dose monotherapy, seizure freedom following conversion to a new monotherapy, or a trial of chronic maintenance 
polytherapy with both the baseline and adjunctive AED. 86    Current Neuropharmacology, 2009, Vol. 7, No. 2 Garnett et al. 
sional patients continue to show improvement, and rarely 
become seizure free, when their AED therapy is dosed well 
beyond the average effective dose for that drug. The only 
limitation in such scenarios is avoiding intolerable dose-
related AED adverse effects such as sedation, cognitive 
slowing, and ataxia. 
  However, for the majority of patients, further aggressive 
titration beyond an average effective AED dose is a largely 
futile enterprise yielding only additional adverse effects and 
little improvement in seizure burden. As such, it is reason-
able to define treatment failure and the practical endpoint of 
initial monotherapy as continued breakthrough seizures oc-
curring despite employing an average effective daily AED 
dosage. Such a patient is evolving toward refractory epilepsy 
even at this point. It is then reasonable and appropriate to 
begin a new adjunctive AED with the plan of converting to a 
second monotherapy, necessitating at least a brief period of 
transitional polytherapy. 
  There are then several possible outcomes and logical 
courses of further treatment (Fig. 1): (1) the patient becomes 
seizure free when the new AED is added and remains seizure 
free with ensuing taper of the primary baseline AED; this 
patient is a successful monotherapy conversion and is treated 
with the newly added drug in monotherapy; (2) the patient 
becomes seizure free on the combination of AEDs during 
transitional polytherapy, has further disabling seizures during 
attempted taper of the initial baseline AED, and becomes 
seizure free again when the baseline primary drug is in-
creased in dose or again reinstituted; this patient is thus best 
treated with a combination of both drugs in chronic mainte-
nance polytherapy; 3) the patient continues having seizures 
despite the combination therapy, and seizure frequency actu-
ally worsens and/or intolerable adverse effects develop dur-
ing titration of the new adjunctive AED; in this instance, 
resumption of the initial AED and another attempted adjunc-
tive AED titration can be offered. 
  Alternatively, the main problem with intitial monother-
apy may be adverse effects. Typical dose-related adverse 
effects include sedation, ataxia, and cognitive slowing. In 
this situation, options include dose reduction of the antiepi-
leptic drug provided the patient remains seizure free, or em-
ploying a new adjunctive AED in transitional polytherapy 
with the goal of converting the patient over to that drug as a 
new second monotherapy. In this situation, adopting a “Flex-
dose” strategy of drug titration (i.e., titrating the new adjunc-
tive AED while tapering the primary baseline AED) is usu-
ally more successful in a patient who is already experiencing 
unpleasant dose-related adverse effects, which are likely to 
become exacerbated further by treatment with two drugs; for 
this reason, it is most reasonable to being a taper of the pri-
mary AED during the period of drug overlap. Potential out-
comes include successful conversion to a new monotherapy 
with the new drug, or chronic maintenance polytherapy 
should the patient continue to have breakthrough seizures 
with attempted withdrawal of the primary baseline AED. The 
reader is again referred to (Fig. 1) for a summary of this ap-
proach, and for further detailed discussion of polytherapy to 
the next article in this series entitled “Truly “Rational” Poly-
therapy: Maximizing Efficacy and Minimizing Drug Interac-
tions, Drug Load, and Adverse Effects.” 
  Drug interactions present a special challenge to transi-
tional polytherapy in the conversion of monotherapy to 
monotherapy. The AEDs are classified as CYP enzyme in-
ducers, enzyme inhibitors, or enzyme neutral drugs. Most 
clinically relevant CYP interactions occur with isozyme sub-
type 3A4, although important inhibitory interactions also 
commonly occur at isozymes 2C9 and 2C19. Similar mecha-
nisms of interaction can occur with induction or inhibition of 
other hepatic metabolic pathways, especially glucuronic acid 
conjugation. The following discussion pertains most to CYP 
level interactions but is also generally relevant to other en-
zymatic systems. 
  AEDs that are themselves inducers or inhibitors have an 
effect on other drugs; specifically, AED inducers or inhibi-
tors may increase or decrease another drug’s metabolism, 
while enzyme neutral AEDs have no effect on the metabo-
lism of other drugs. AEDs that have enzyme induction and 
inhibition properties have such effects on other AEDs as well 
as non-AED drugs used for treatment of other concurrent 
diseases, such as anticoagulants, antihypertensives, choles-
terol-lowering drugs, and oral contraceptives. Also, the me-
tabolism of some AEDs, even those that are themselves en-
zyme-neutral, may be impacted by other drugs that are in-
ducers or inhibiters. Drug interactions may also occur when 
adding a new drug or when discontinuing a drug that the 
patient has been on for an extended period. For example, 
phenytoin is an enzyme inducer that increases the metabo-
lism of many other drugs. During transitional polytherapy 
with phenytoin and another inducible drug, when phenytoin 
is added, the metabolism of the other inducible drug is in-
creased, as is its serum clearance, so the serum concentration 
of the inducible drug decreases. However, if phenytoin and 
another inducible drug is being used in combination and 
phenytoin is removed, the elimination of the other inducible 
drug will be reduced, and it will instead accumulate and the 
serum concentration of the inducible drug will increase. This 
could lead to dangerous complications such as bleeding 
when the inducible co-medication involved is an anticoagu-
lant such as warfarin. The opposite is true for an AED that is 
an enzyme inhibitor, such as valproic acid, topiramate, or 
oxcarbazepine. These enzyme inhibiting AEDs may result in 
reduced clearance and subsequent accumulation, leading to 
increased serum concentrations of a co-medication. While 
most of the focus of drug-drug interactions is on pharma-
cokinetic interactions of enzyme induction or inhibition, 
there are some other drugs that have pharmacodynamic in-
teractions. A pharmacodynamic interaction probably occurs 
at the receptor site. For example, the addition of lamotrigine 
to the drug regimen of a patient taking carbamazepine may 
result in a higher incidence of CNS side effects. However, 
lamotrigine does not interfere with the metabolism of either 
carbamazepine or its active 10-11 diepoxide metabolite. 
  AEDs have very different clinical pharmacology and 
clinical pharmacokinetic profiles. It is important to review 
these profiles in evaluating rates and methods of transitional 
polytherapy from monotherapy to monotherapy. 
CLINICAL PHARMACOLOGY OF AEDS 
  A complete review of clinical pharmacology of the AEDs 
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the route of elimination, half-life, and potential for drug in-
teractions are important factors to consider in transitional 
polytherapy. These factors will influence the rate of dosage 
titration and withdrawal. 
Carbamazepine (Tegretol, Tegretol-XR, Carbatrol,   
Others) 
  The principle mechanism of action of carbamazepine is 
thought to relate to blockade of voltage-dependent sodium 
channels. Carbamazepine is eliminated by hepatic metabo-
lism and is metabolized to an active metabolite, 10-11 car-
bamazepine epoxide [2]. The concentration of the parent 
drug and the metabolite may vary independently. Carba-
mazepine is unique in that it induces its own metabolism and 
the half-life of carbamazepine becomes shorter with contin-
ued dosing. The metabolism of carbamazepine may be in-
duced or inhibited, principally by CYP 3A4, and carba-
mazepine will induce the metabolism of other AEDs and 
non-AED drugs. A limitation of carbamazepine is its asso-
ciation with rare but severe idiosyncratic adverse effects 
such as fatal hepatic injury or Stevens Johnson Syndrome 
(SJS) [11,17]. Patients of Asian ancestry may be particularly 
vulnerable to evolution of SJS, and it is recommended by 
FDA in the United States that patients of Han Chinese ances-
try in particular, and others of Asian ancestry who com-
monly express this genotype, receive preliminary testing for 
the HLA-B*1502 susceptibility allele for SJS prior to initiat-
ing carbamazepine therapy [15]. 
Felbamate (Felbatol) 
  Felbamate is also presumed to have a major mechanism 
of action of voltage-dependent sodium channel blockade, but 
it also blocks glutamatergic NMDA receptors [33]. The as-
sociation of aplastic anemia and hepatotoxicity with felba-
mate have restricted the use of this AED to those with brittle, 
refractory epilepsy [34]. Felbamate is eliminated renally and 
hepatically. The metabolism may be inhibited and induced. 
Felbamate will inhibit the metabolism of some drugs (eg, 
phenytoin, valproic acid, carbamazepine epoxide) and induce 
others (eg, carbamazepine). 
Gabapentin (Neurontin, Others) 
  Gabapentin binds to the alpha2—delta1 subunit of the 
presynaptic calcium channel, modulating neurotransmitter 
release [45]. Gabapentin is actively absorbed. It binds to an 
L-amino protein carrier system in the gut and this system 
may become saturated. Therefore, the bioavailability of 
gabapentin decreases as the dose increases sometimes neces-
sitating more frequent dosing. Gabapentin is eliminated 
renally, and the clearance of gabapentin correlates with the 
creatinine clearance [38]. 
Lacosamide (Vimpat) 
  Lacosamide is a novel AED with a presumed mechanism 
of action related to slow sodium channel inactivation, possi-
bly to modulation of collapsin response mediator protein-2 
(CRMP-2) binding that modulates neutrophic factors [10].
This AED is rapidly and completely absorbed, reaches a 
peak concentration in one hour with a 13-hour elimination 
half-life, and has a linear concentration curve up to dosing of 
800 mg/day [10]. Lacosamide has minor metabolism to an 
inactive O-desmethyl metabolite and is cleared renally. No 
significant CYP induction/inhibition, nor any drug interac-
tion with other AEDs or common prescription drugs have 
been reported. 
Lamotrigine (Lamictal) 
  The principle mechanism of action for lamotrigine is 
blockage of voltage gated sodium channels [16]. Lamo-
trigine is eliminated almost completely by Phase II hepatic 
metabolism. While the half-life of lamotrigine is around 22 
hours in drug naïve patients, indicating that once-a-day dos-
ing would be feasible, the metabolism may be induced or 
inhibited [16]. The half-life of lamotrigine in patients taking 
enzyme inducers is around 12 hours [21]. The clearance of 
lamotrigine is significantly reduced in patients taking val-
proic acid, due to inhibition of lamotrigine’s glucuronidation 
by valproate [51]. Unless the dose of lamotrigine is very 
slowly increased, the use of valproic acid and lamotrigine 
together is associated with an increase in the incidence of 
skin rash. While the metabolism of lamotrigine may be in-
duced or inhibited, it does not alter the metabolism of other 
drugs. Oral contraceptives have been reported to decrease the 
serum concentration of lamotrigine, potentially rendering it 
less effective and requiring dose supplementation [39]. A 
similar phenomena of female hormones lowering lamo-
trigine’s concentration is also seen during pregnancy, as the 
serum concentration of lamotrigine may decrease as preg-
nancy progresses toward full term, then rises again in the 
postpartum state [47]. The dose of lamotrigine must be in-
creased slowly because of the increased incidence of skin 
rash with a rapid dosage titration. 
Levetiracetam (Keppra) 
  Levetiracetam binds the presynaptic SV2A synaptic vesi-
cle protein, which appears to be its principle mechanism of 
action [31,46]. Most of levetiracetam is eliminated renally 
with minor elimination via hydrolysis that does not involve 
liver enzymes [1]. The metabolism of levetiracetam is not 
induced or inhibited, and levetiracetam does not interact with 
other drugs. The dose of levetiracetam may need to be re-
duced in patients with renal impairment. Due to its generally 
excellent tolerability, levetiracetam dosage can generally be 
increased rapidly. 
Oxcarbazepine (Trileptal) 
  Oxcarbazepine is a prodrug and is rapidly converted to a 
monohydroxylated derivative (MHD) which is active [42]. 
MHD is eliminated by glucuronide conjugation or hydroxy-
lation as well as renally. Patients with renal dysfunction have 
a decreased clearance of MHD. Although this drug is struc-
turally and mechanistically related to carbamazepine, there is 
no auto induction [40]. While the metabolism of oxcar-
bazepine to MHD is not induced or inhibited, the further 
metabolism of MHD may be altered by other drugs; in par-
ticular, the metabolism of MHD is inducible at CYP 3A4 
[42]. Also, oxcarbazepine or MHD may interact with other 
drugs; an important interaction is the possibility of reduced 
hormonal contraceptives concentrations in women of child 
bearing potential receiving oxcarbazepine [14]. Oxcar-
bazepine may have favorable impact upon mood in patients 
with epilepsy [32].88    Current Neuropharmacology, 2009, Vol. 7, No. 2 Garnett et al. 
Phenobarbital (Luminal) 
  Phenobarbital is the oldest AED still in active use and 
remains the most commonly used AED worldwide, particu-
larly in the treatment of neonatal seizures where it remains a 
drug of choice given extensive experience with its use in this 
patient population [6,28]. However, the use of Phenobarbital 
has waned substantially in the United States and Europe 
given its inferior tolerability to other older drugs and the 
newer AEDs [28]. The main mechanism of action of pheno-
barbital is related to increased duration of opening of the 
chloride ionophore by binding the alpha subunit of the 
GABA-A receptor complex [28]. Phenobarbital has both 
hepatic and renal elimination. The half-life of phenobarbital 
ranges from 72 to 125 hours, necessitating very slow dosage 
adjustment. The metabolism of phenobarbital may be inhib-
ited or induced. Phenobarbital is a potent CYP enzyme in-
ducer. 
Phenytoin (Dilantin, Phenytek, Others) 
  The main mechanism of action for phenytoin is blockade 
of voltage gated sodium channels. Phenytoin has very com-
plex pharmacokinetics displaying saturable absorption, satu-
rable metabolism (Michaelis-Menton kinetics), and high 
protein binding [23]. This drug is eliminated primarily by 
hepatic metabolism. However, the half-life is concentration 
dependant due to saturable metabolism. Saturable metabo-
lism means that small changes in dose may result in signifi-
cantly larger increases in serum concentration. The metabo-
lism of phenytoin may be inhibited or induced, and pheny-
toin induces the metabolism of other drugs. 
Pregabalin (Lyrica) 
  Like its structural analog gabapentin, the main mecha-
nism of pregabalin appears to be related to binding at the 
alpha2—delta1 subunit of the presynaptic calcium channel, 
modulating neurotransmitter release [44]. 
  Although this drug is structurally related to gabapentin, 
the pharmacokinetics of pregabalin are linear because pre-
gabalin does not display the saturable absorption shown by 
gabapentin [12]. Pregabalin is completely eliminated renally 
and is not protein bound. Patients with renal impairment will 
have a decreased pregabalin clearance. There are no drug 
interactions reported with pregabalin. The dose of pregabalin 
may be rapidly increased as tolerated, although many pa-
tients require slower titration due to CNS adverse effects. 
Rufinamide (Banzel) 
  This triazole derivative is structurally unrelated to cur-
rently marketed AEDs, and its major mechanism of action 
appears to be related to prolonged inactivation of sodium 
channels [3]. The extent of rufinamide absorption decreases 
with higher dosing. The drug is extensively metabolized by 
carboxylase enzymatic degradation to an inactive carboxylic 
acid, and renally cleared. Rufinamide is a weak CYP3A4 
inducer, so it may impact metabolism of other AEDs and 
medications cleared through CYP3A4 including hormonal 
contraceptives. Plasma half-life is 6-10 hours. Rufinamide 
may increase phenytoin concentrations to some degree, but 
has no significant effects on other AEDs. Valproate de-
creases rufinamide clearance in children by up to 70%, so 
titration of either drug should be adjusted accordingly when 
rufinamide and valproate are co-administered. 
Tiagabine (Gabatril) 
  The presumed mechanism of action is related to its activ-
ity as a potent and selective blocker of the GAT-1 GABA 
transporter, thereby inhibiting reuptake of GABA into pre-
synaptic neurons and prolonging its availability synaptically 
[22,49].Tiagabineiseliminatedbyhepatic metabolism, which 
can be induced or inhibited. However, this drug is not re-
ported to affect the metabolism of other drugs. Tiagabine is 
highly protein bound. The dose of tiagabine must be slowly 
increased because of increased side effects with rapid dosage 
titration. 
Topiramate (Topamax) 
  The main mechanism of action of topiramate is thought 
to be related to voltage gated sodium ion channel blockade, 
but it also has a variety of other synaptic and non-synaptic 
effects, including blockade of glutamatergic non-NMDA 
kainate/AMPA receptors, facilitation of GABAergic neuro-
transmission, and mild inhibition of carbonic anhydrase [41]. 
Topiramate has both renal and liver elimination. However, 
the renal elimination predominates. In patients with hepatic 
dysfunction, renal elimination may increase [19]. Patients 
with decreased renal function will have a decreased clear-
ance of topiramate. Enzyme inducers increase clearance of 
topiramate. Topiramate inhibits the metabolism of some pa-
tients taking phenytoin but not all. The interaction appears to 
occur in those patients who are at the point of saturating their 
phenytoin metabolism [23]. The dose of topiramate must be 
slowly increased because the incidence of side effects may 
increase with a rapid dosage titration, especially when topi-
ramate is used in adjunctive therapy with other AEDs. The 
propensity for topiramate adverse effects with monotherapy 
use appears to be substantially lower than when topiramate is 
used in adjunctive therapy settings [36].
Valproic acid (Sodium Divalproex) (Depakene, Depakote, 
Depakote-ER) 
  Valproate also has a predominant mechanism of action 
related to blockade of voltage gated sodium channels, but 
there is also evidence for additional mechanisms including 
facilitation of GABAergic neurotransmission and inhibition 
of glutamatergic neurotransmission via NMDA receptor in-
hibition [30]. The rate of absorption of valproic acid depends 
on the formulation; the sodium salt with enteric coating (De-
pakote) is well absorbed, while the generic valproic acid 
formulation (Depakene) is poorly absorbed and often causes 
nausea, especially during initial titration. Valproic acid is 
metabolized by the liver by Phase II metabolism to multiple 
metabolites, one of which may be liver toxic [37]. Valproic 
acid is highly protein bound. However, the binding saturates 
at concentrations around 90 mcg/mL. This increases the free 
fraction, which increases the clearance. Thus, the percent 
increase in total concentration will be less than the percent 
increase in dose.  
Zonisamide (Zonegran) 
  The principle mechanism for zonisamide again appears to 
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nels, limiting sustained neuronal burst firing, but it also has 
several additional mechanisms, including inhibition of low-
threshold T-type calcium channels and weak inhibition of 
carbonic anhydrase [5]. About 70% of zonisamide is metabo-
lized in the liver and about 30% is eliminated renally [24]. 
While the metabolism of zonisamide may be induced or in-
hibited, zonisamide does not alter the clearance of other 
drugs. The dose of zonisamide should be slowly increased to 
reduce the incidence of side effects, especially CNS side 
effects. 
  While the need for transitional polytherapy in the conver-
sion of monotherapy to monotherapy has been established 
clinically, there are few published papers on how this should 
be done. While some have considered this to be more art 
than science, a recent panel of experts was convened to es-
tablish standard recommendations to guide all clinicians in 
transitional polytherapy. 
SPECTRA CONSENSUS PANEL RECOMMENDA-
TIONS  
  There is very little published data to assist the clinician in 
determining the rate of upward titration and downward taper 
of AEDs during the process of transitional polytherapy from 
monotherapy to monotherapy. A panel of neurologists and 
clinical pharmacists who specialize in the care of patients 
with epilepsy was assembled to participate in a therapy con-
version Delphi study called SPECTRA (Study by a Panel of 
Experts: Considerations for Therapy Replacement in Antie-
pileptics). The goal of SPECTA was to develop a practical 
guide on AED monotherapy conversion, and the consensus 
recommendations were recently published [45]. 
  The process involved two web-based surveys and one 
live consensus panel. In the first web-based survey, panel 
members were asked questions about therapy conversion in 
adults. The second web-based survey responded to the an-
swers from the first survey. The questionnaires used the Del-
phi technique to elicit individual responses and facilitate the 
experts in refining their views as the group proceeded to 
agreement. Delphi is a group facilitation technique that seeks 
to obtain consensus on the opinions of experts through a se-
ries of structured questionnaires commonly referred to as 
rounds. This technique maintains anonymity, controls feed-
back, and provides statistically based responses. After the 
second web-based survey, the group was convened to reach 
consensus on the rate of tapering of the old AED, the rate of 
titration of the new AED, and the usefulness of drug level 
monitoring. During the third round, panel members reviewed 
each statement and voted anonymously using an automated 
response system (ARS). The response options ranged from 1 
to 5, where 1 = strongly disagree, 2 = disagree, 3 = neutral, 4 
= agree, and 5 = strongly agree. Generally, a mean score of 
4.0 (agree) was required to indicate that consensus had been 
reached. The panel did not feel that sufficient experience or 
literature existed to provide recommendations regarding the 
approved AED pregabalin (Lyrica), nor did they consider 
lacosamide (Vimpat) or rufinamide (Banzel) since these 
drugs were investigational at the time the panel was con-
vened. 
  The panel reached a consensus for the following recom-
mendations for a general taper and titration.  
Starting a Taper 
  The panel recommended that the old baseline AED be 
tapered after a presumably efficacious dose was reached with 
the new planned AED. However, if a patient experienced 
significant adverse effects during the conversion, the taper of 
the old baseline AED may be started sooner. 
Tapering 
  The panel recommended slower tapering and smaller 
reductions for persons who are seizure free and licensed to 
drive for all agents. However, in 10 out of 12 drugs re-
viewed, a faster taper was recommended if a patient experi-
enced significant adverse events. The exceptions were car-
bamazepine and valproic acid. The panel only recommended 
a slower taper if patients experienced inadequate seizure 
control when receiving tiagabine and topiramate. General 
drug specific tapering strategies are depicted in (Fig. 2), and 
drug specific alterations to the general tapering strategy are 
summarized in Table 1.
Titration
 
Fig. (2). General Tapering Method. Note that phenobarbital, with 
a 10-25% reduction of original dose every month, is not illustrated. 
CBZ, carbamazepine; FBM, felbamate; GBP, gabapentin; LEV, 
levetiracetam; LTG, lamotrigine; OXC, oxcarbazepine; PB, pheno-
barbital; PHT, phenytoin; TGB, tiagabine; TPM, topiramate; VPA, 
valproate; ZNS, zonisamide. (reproduced with kind permission 
from Elsevier, Inc. St. Louis et al; Conversions between mono-
therapies in epilepsy: expert consensus. Epilepsy and Behavior
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  After reviewing the package inserts titration schedules, 
the panel agreed with this method for lamotrigine, tiagabine, 
and zonisamide. For the nine other AEDs, they recom-
mended additional methods to assist with titration and taper-
ing processes. Factors such as enzyme inducers and ad-
vanced age modified titration schemes. 
  The panel reached a consensus on the taper and titration 
of individual AEDs. Drug specific general titration strategies 
are summarized in Table 2 , and alterations to the general 
titration strategies are shown in Table 3.
Carbamazepine  
  The general taper is 20% of the original dose every week. 
A faster taper was recommended for patients with reduced 
liver function and patients being converted to oxcarbazepine. 
A larger reduction in dose was recommended for patients 
with significant adverse effects. A smaller reduction in dose 
was recommended for patients with inadequate seizure con-
trol.  
  The initial dose recommended for carbamazepine was 
200 mg/day with a dosage increase of 200 mg every 7 days. 
After a total daily dose of 400 to 800 mg/day was achieved, 
the panel would use drug levels to determine the next course 
of action. A faster titration was recommended in patients 
with inadequate seizure control or for patients who were 
converting from oxcarbazepine. A slower titration was rec-
ommended for elderly patients, patients with reduced liver 
function, patients with mild adverse effects, or patients con-
verting from felbamate. A larger increase in dose was rec-
ommended for inadequate seizure control, and a smaller in-
crease in dose was recommended for elderly patients. 
Felbamate 
  The panel recommended that the general taper for felba-
mate be 25% of the original dose every week. The taper 
Table 1.  Summary of Drug Specific Alterations to General Tapering Methods. Antiepileptic Drugs (AEDs) are listed alphabetically. 
The SPECTRA Panel reached consensus for modification of the usual general tapering method for each drug in certain situations, 
and recommended faster or slower tapering, by larger or smaller dose decrements, in the situations listed in each column for each 
individual AED. CBZ, carbamazepine; FBM, felbamate; GBP, gabapentin; LEV, levetiracetam; LTG, lamotrigine; OXC, oxcar-
bazepine; PB, phenobarbital; PHT, phenytoin; TGB, tiagabine; TPM, topiramate; VPA, valproate; ZNS, zonisamide. (modified 
and reproduced with kind permission from Elsevier, Inc. St. Louis et al; Conversions between monotherapies in epilepsy: expert 
consensus. Epilepsy and Behavior 2007; 11: 226).
AED  Faster Taper  Slower Taper  Larger Dose Decrements  Smaller Dose Decrements 
1. CBZ  Impaired liver function 
Conversion to OXC 
  Significant adverse effects   Inadequate seizure control 
2. FBM  Impaired liver function 
Significant adverse effects 
  Inadequate seizure control  Impaired liver function 
3. GBP  Renal insufficiency 
Significant adverse effects 
  Significant adverse effects  Inadequate seizure control 
4. LTG  Impaired liver function 
Converting to VPA 
Significant adverse effects 
 Impaired  liver  function 
Converting to VPA 
Inadequate seizure control 
5. LEV  Renal insufficiency 
Significant adverse effects 
Significant adverse effects Renal 
insufficiency 
Inadequate seizure control 
6. OXC  Converting to CBZ 
Significant adverse events 
  Significant adverse effects 
Converting to CBZ 
Inadequate seizure control 
7. PB  On PB <1 month 
Significant adverse effects 
  Significant adverse effects  Inadequate seizure control 
8. PHT  Impaired liver function 
Significant adverse effects 
 Impaired  liver  function   
9. TGB  Impaired liver function 
Significant adverse effects 
Inadequate seizure control  Impaired liver function   
10. TPM  Renal insufficiency 
Significant adverse effects 
Inadequate seizure control  Renal insufficiency  Inadequate seizure control 
11.VPA  Impaired liver function    Impaired liver function   
12. ZNS  Significant adverse effects    Inadequate seizure control   Transitional Polytherapy  Current Neuropharmacology, 2009, Vol. 7, No. 2    91
Table 2.  Summary of Drug Specific General Titration Methods. The SPECTRA panel provided consensus recommendations for gen-
eral strategies of titrating each of the antiepileptic drugs (AEDs) shown below. Recommended starting doses, titration schemes,
and target doses were agreed upon for each AED. The final column indicates whether or not the panel reached consensus regard-
ing a recommendation for blood level monitoring during titration. CBZ, carbamazepine; FBM, felbamate; GBP, gabapentin; LEV, 
levetiracetam; LTG, lamotrigine; OXC, oxcarbazepine; PB, phenobarbital; PHT, phenytoin; TGB, tiagabine; TPM, topiramate; 
VPA, valproate; ZNS, zonisamide. (reproduced and modified with kind permission from Elsevier, Inc. St. Louis et al; Conver-
sions between monotherapies in epilepsy: expert consensus. Epilepsy and Behavior 2007; 11: 225).
AED  Starting Dose  Interval (Increase)  Target Daily Dose  Monitor Blood Level 
During Titration 
1. CBZ  200 mg/day  200 mg every 7 days  400-800 mg/day
a Yes 
2. PBM  600 mg/day  300 mg every 7 days  1200-1800 mg/day  No consensus 
3. GBP  600-900 mg/day  600-900 mg every 7 days  1800-2700 mg/day  No consensus 
4. LTG
b
 Package insert 
 Existing AED is CBZ, PHT, PB 
or primidone  
 Existing AED is VPA 
 Existing AED is not CBZ, PHT, 
PB VPA or primidone  
50 mg/day 
25 mg every other 
day
25 mg every day 
50 mg every day for 2 weeks. 100 mg 
every day for weeks 3 and 4; then 100 mg 
every week 
25 mg every other day for 2 weeks. 25 mg 
every day for weeks 3 and 4. 50 mg every 
day for week 5.  
25-50 mg every 1-2 weeks. 50 mg every 
day for weeks 3 and 4. 100 mg every day 
every 7 days 
200-500 mg/day 
100-200 mg/day 
300-500 mg/day 
No consensus 
No consensus 
No consensus 
5. LEV  500-1000 mg/day  500-1000 mg every 7 days  1000-2000 mg/day  No consensus 
6. OXC  300-600 mg/day  300 mg every 7 days  900-1500 mg/day  No consensus 
7. PB
c        
8. PHT  3-5 mg/kg/day  30 mg/day if steady state 
Level >12 Eg/mL: 
50 mg /day if steady state 
Level 7-12 Eg/mL 
100 mg/day if steady state 
Level <7 Eg/mL 
Therapeutic blood 
level 
Yes 
9. TGB 
 Package insert 
 Existing drug is enzyme-inducer 
 Existing drug not an enzyme-
inducer
d
4 mg/day  4 mg every 7 days for 4 weeks. 4-8 mg 
every 7 days in weeks 5 and 6. 
32-56 mg/day in 2-4 
divided doses 
No consensus 
10. TPM  25-50 mg/day  25-50 mg every 7 days  100-200 mg/day  No consensus 
11. VPA  500-1000 mg/day  250-750 mg every 7 days  1000-2000 mg/day
e Yes 
12. ZNS 
 Package insert 
100 mg/day  100 mg every 2 weeks  300-400 mg/day  No consensus 
aFor CBZ, use higher end of target daily dose if converting from an enzyme inducer. 
b For LTG, titration schemes outlined are taken from US packaging insert guidelines: international clinicians are advised to consult package insert recommendations and approvals in 
countries, which may differ from US standards. 
c Titration with PB is not encouraged (the SPECTRA panel decided not to provide specific recommendations regarding phenobarbital, reflecting a general discouragement for use of 
phenobarbital in modern epilepsy treatment). 
d Following a given dose of TGB, the estimated plasma concentration in non-induced patients is more than twice that in patients receiving enzyme-inducing  agents. Use in non-
induced patients requires lower doses of TGB. These patients may also require a lower titration of TGB. These patients may also require a slower titration of TGB compared with 
induced patients. 
eFor VPA, use lower end of range for generalized seizures.  92    Current Neuropharmacology, 2009, Vol. 7, No. 2 Garnett et al. 
Table 3.  Summary of Drug Specific Alterations to General Titration Methods. Antiepileptic Drugs (AEDs) are listed alphabetically. 
The SPECTRA Panel reached consensus for modification of the usual general titration schemes for each drug in certain situations,
and recommended faster or slower tapering, by larger or smaller dose decrements, in the situations listed in each column for each 
individual AED. CBZ, carbamazepine; FBM, felbamate; GBP, gabapentin; LEV, levetiracetam; LTG, lamotrigine; OXC, oxcar-
bazepine; PB, phenobarbital; PHT, phenytoin; TGB, tiagabine; TPM, topiramate; VPA, valproate; ZNS, zonisamide. (reproduced 
and modified with kind permission from Elsevier, Inc. St. Louis et al; Conversions between monotherapies in epilepsy: expert 
consensus. Epilepsy and Behavior 2007; 11: 226).
AED  Faster Titration  Slower Titration  Larger Dose Increments  Smaller Dose Increments 
1. CBZ  Inadequate seizure control 
Conversion from OXC 
Elderly patient 
Impaired liver function 
Mild adverse effects 
Converting from FBM 
Inadequate seizure control  Elderly patient 
2. FBM
a   Mild adverse effects  Inadequate seizure control  Impaired liver function 
3. GBP  Inadequate seizure control  Elderly patient 
Renal insufficiency 
Mild adverse effects 
Inadequate seizure control   
4. LTG
b   Mild adverse effects 
Converting to VPA
c
Inadequate seizure control  Impaired liver function 
5. LEV  Inadequate seizure control  Elderly patient 
Renal insufficiency 
Mild adverse effects 
Inadequate seizure control  Elderly patient 
6. OXC  Converting from CBZ 
Inadequate seizure control 
Impaired liver function  Inadequate seizure control 
Converting from CBZ 
Impaired liver function 
7. PB
d      
8. PHT
e      
9. TGB  Inadequate seizure control  Elderly patient 
Impaired liver function 
Mild adverse effects 
Inadequate seizure control  Impaired liver function 
Elderly patient 
10. TPM  Inadequate seizure control  Renal insufficiency  Inadequate seizure control  Elderly patient 
Renal insufficiency 
11. VPA    Elderly patient 
Mild adverse effects
f
Inadequate seizure control  Elderly patient 
12. ZNS  Inadequate seizure control  Elderly patient  Inadequate seizure control  Elderly patient 
Note: All references to package insert refer to US packaging: international clinicians are encouraged to consult packaging information and recommended prescribing practices in their 
own countries, which may vary substantially from US standards.  
aFBM should not be used by a nonepileptologist: should not be used in elderly patients: and should not be used in patients with impaired liver function.  
bShould refer to package insert when converting from PHT. 
cShould refer to package insert when converting from VPA. 
d Titration with PB is not encouraged (the SPECTRA panel decided not to provide specific recommendations regarding phenobarbital, reflecting a general discouragement for use of 
phenobarbital in modern epilepsy treatment). 
eNo alterations to the general titration method are recommended. 
fAdverse events are final dose related, not titration related.  
could be faster in patients with reduced liver function and in 
patients with significant adverse effects. The percent dose 
reduction could be larger in patients with reduced liver func-
tion and smaller in patients with inadequate seizure control. 
  The recommended starting dose was 600 mg/day. The 
dose could be increased by 300 mg every 7 days to a target 
dose of 1200 to 1800 mg/day. A slower titration was recom-
mended for patients with mild side effects. The panel felt 
that this AED should only be used by epileptologists. They 
did not want to encourage the use of felbamate in the elderly 
or in patients with reduced liver function and, therefore, did 
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Gabapentin 
  The general taper recommended for gabapentin was 25% 
of the original dose every week. A faster taper would be ac-
ceptable for patients with renal insufficiency or patients with 
significant adverse effects. A larger dose reduction would be 
acceptable for patients with significant adverse effects, and a 
smaller reduction would be acceptable for patients with in-
adequate seizure control. 
  As the initial dose of gabapentin, 600 to 900 mg/day was 
recommended, with an increase of 600 to 900 mg every 7 
days to a total dose of 1800 to 2700 mg. A faster titration 
was recommended for inadequate seizure control. A slower 
titration was recommended for elderly patients, patients with 
renal insufficiency, and patients with mild adverse effects. A 
larger dose increase was recommended for patients with in-
adequate seizure control.  
Lamotrigine 
  A reduction of 20% to 25% of the original dose was rec-
ommended as the general taper of lamotrigine. A faster taper 
was recommended for patients with reduced liver function, 
patients taking valproic acid, and patients with significant 
adverse effects. A larger dosage reduction was endorsed for 
patients with reduced liver function and for patients convert-
ing to valproic acid monotherapy, while a smaller reduction 
in dose was endorsed for patients with inadequate seizure 
control. 
  The panel accepted the package insert recommendations 
for the starting dose and for the dosing interval. After a dose 
of 200 to 500 mg/day was reached, the panel recommended 
that levels be used to determine the next course of action. 
The panel did not recommend any faster rate of titration but 
did recommend a slower rate of titration for patients with 
mild adverse effects and for patients who were converting 
from valproic acid. A larger dosage increase was recom-
mended for patients with inadequate seizure control, and a 
smaller dosage increase was recommended for patients with 
reduced liver function. The panel referred clinicians to the 
package insert for dosage adjustments for patients converting 
from valproic acid or enzyme-inducing AEDs. 
Levetiracetam 
  The panel recommended that a general taper of leveti-
racetam begin with a 20% to 25% reduction in the original 
dose every week. The taper may be faster in patients with 
renal insufficiency or significant adverse effects. The percent 
reduction may be larger in patients with significant adverse 
effects or renal insufficiency and smaller in patients with 
inadequate seizure control. 
  A starting dose of 500 to 1000 m/day of levetiracetam 
was recommended. The recommended dosing interval was 
500 to 1000 mg every 7 days to a target dose of 1000 to 2000 
mg/day. A faster titration was endorsed for patients with 
inadequate seizure control. A slower titration was recom-
mended for elderly patients, patients with renal insufficiency, 
and patients with mild adverse effects. A larger dose increase 
was recommended for patients with inadequate seizure con-
trol, and a smaller increase was recommended for elderly 
patients. 
Oxcarbazepine 
  The general taper recommended for oxcarbazepine was 
20% to 25% of the original dose every week. A faster taper 
was approved for patients converting from carbamazepine 
and for patients with significant adverse effects. No recom-
mendations were made for a slower taper. A larger dose re-
duction was deemed appropriate for patients with significant 
adverse side effects and for patients converting from carba-
mazepine monotherapy. A smaller reduction was acceptable 
for patients with inadequate seizure control. 
  The recommended starting dose of oxcarbazepine was 
300 to 600 mg/day. A 300 mg increase in dose every 7 days 
was recommended up to a target dose of 900 to 1500 mg/ 
day. A faster rate of titration was acceptable for patients with 
inadequate seizure control and for patients converting from 
carbamazepine, while a slower titration was acceptable for 
patients with reduced liver function. A larger dosage increase 
was agreed upon for patients with inadequate seizure control 
and for those patients who are converting from carba-
mazepine, while a smaller increase was recommended for 
patients with reduced liver function. 
Phenobarbital 
  The general taper that was recommended for phenobarbi-
tal was 10% to 25% of the original dose every month. A 
faster taper was recommended for patients on phenobarbital 
less than 1 month and for those with significant adverse ef-
fects. No recommendations were made for a slower taper. A 
larger reduction in dose was recommended for patients with 
significant adverse effects, while a smaller reduction was 
recommended for patients with inadequate seizure control. 
  The panel did not make any recommendations for pheno-
barbital titration, as switching a patient to Phenobarbital was 
not encouraged. 
Phenytoin 
  A 20% to 25% reduction of the original dose every 
month was recommended as a general taper for phenytoin. A 
faster taper was recommended for patients with reduced liver 
function or significant adverse effects. A larger reduction in 
dose was recommended for patients with reduced liver func-
tion. No recommendations were made for a slower taper or 
for a smaller reduction in dose. 
  The recommended starting dose of phenytoin was 3 to 5 
mg/kg/day. The recommended dosage adjustments were 30 
mg/day for steady state levels >12 mcg/mL, 50 mg/day for 
steady state levels between 7 and 12 mcg/mL, and 100 
mg/day for steady state levels <7 mcg/mL [35]. The target 
dose was dependant on the drug level. 
Tiagabine 
  The general taper recommended for tiagabine was 20% to 
25% of the original dose every week. A faster taper may be 
appropriate for patients with reduced liver function or pa-
tients with significant adverse effects, and a slower taper 
may be appropriate for patients with inadequate seizure con-
trol. The panel recommended a larger reduction in dose for 
patients with reduced liver function but did not make any 
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  The panel accepted the package insert suggestions for 
dosage titration. A faster titration was recommended for pa-
tients with inadequate seizure control, and a slower titration 
was recommended for elderly patients, patients with reduced 
liver function, and patients with mild adverse effects. The 
panel recommended a larger dose increase in patients with 
inadequate seizure control, and a smaller dosage increase in 
elderly patients and patients with reduced liver function. 
Topiramate 
  A 20% to 25% reduction of the original dose every week 
was recommended as the general taper for topiramate. A 
faster taper was recommended for patients with renal insuffi-
ciency or significant adverse effects. A slower taper was 
recommended for patients with inadequate seizure control. A 
larger reduction in dose was recommended for patients with 
renal insufficiency, and a smaller reduction in dose was rec-
ommended for patients with inadequate seizure control. 
  The initial dose that was recommended was 25 to 50 
mg/day with dosage increases of 25 to 50 mg every 7 days 
up to 100 to 200 mg/day. Faster titration was recommended 
for patients with inadequate seizure control, and a slower 
titration was recommended for patients with renal insuffi-
ciency. A larger increase in dose was recommended for pa-
tients with inadequate seizure control, and a smaller increase 
in dose was recommended for elderly patients and patients 
with renal insufficiency. 
Valproate (Valproic Acid, Sodium Divalproex) 
  The general taper that was recommended for valproate 
was 20% to 25 % of the original dose every week. A faster 
taper and a larger dosage reduction were recommended for 
patients with reduced liver function. No recommendations 
were made for slower tapers or smaller dosage reduction. 
  For the starting dose of valproate, 500 to 1000 mg/day 
was recommended. Dosage increases of 250 to 750 mg every 
7 days were recommended up to a dose of 1000 to 2000 
mg/day. Blood levels would then determine the next course 
of action. The panel made no recommendation for faster 
dosage titration but recommended a slower titration in eld-
erly patients and patients with mild adverse effects. The 
panel recommended a larger increase in dose for patients 
with inadequate seizure control and a smaller increase in 
dose for elderly patients.  
  The panel also agreed that the adverse effects of val-
proate are final-dose related and are not usually titration re-
lated. The panel concluded that the target concentration of 
valproate for general seizures is on the lower end of the tar-
get concentrations. 
Zonisamide 
  A 20% to 25% reduction of the original dose every week 
was recommended as the general taper for zonisamide. A 
faster titration and larger increase and dosage for patients 
with inadequate seizure control. No recommendations were 
made for a slower taper or for a smaller dosage reduction. 
  The panel accepted the package insert method for initiat-
ing and titrating zonisamide. The panel recommended a 
faster titration and larger increase in dosage reduction for 
patients with inadequate seizure control and a slower titra-
tion and a smaller dosage increase for elderly patients. 
Blood Level Monitoring 
  The panel also discussed drug level monitoring during 
transitional polytherapy from monotherapy to monotherapy, 
recommending drawing a drug level for the new AED before 
withdrawing the old AED. The panel also recommended 
obtaining a level of the new AED once the patient is on 
monotherapy to be used as a baseline or benchmark level to 
which future comparisons could be made when necessary. 
Examples of scenarios in which a previously efficacious, 
steady-state AED dosing and concentration could be threat-
ened include problems with patient adherence, new drug-
drug interactions, new medical illness, or pregnancy. 
CONCLUSION 
  The concept of monotherapy for the treatment of epilepsy 
is well established. However, at least 50% of patients fail 
therapy with the first AED. Conversion from one AED to 
another is complex. Generally, sudden withdrawal of initial 
AED therapy is discouraged unless a patient has experienced 
serious adverse effects. In most instances when patients are 
changing from one AED to another, there will be a period of 
transitional polytherapy during the conversion from mono-
therapy to monotherapy. This process is complicated by drug 
interactions and complex AED pharmacokinetics.  
  Until now, physicians have had to rely on their own 
clinical experience to determine the rate of AED tapering 
and titration. The SPECTRA report utilized the well-
validated Delphi technique to achieve consensus from prac-
ticing epileptologists and clinical pharmacists on tapering 
and titrating AEDs. Now there is a set of guidelines that cli-
nicians can use to compare their clinical experiences and aid 
them in the period of transitional polytherapy with antiepi-
leptic drugs from monotherapy to monotherapy. 
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